SAGE Therapeutics (SAGE) Posts Q4 Loss of ~$1.57/Share
SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of about ($1.57), $1.13 worse than the analyst estimate of ($0.44).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.